Abstract
The development and characteristics of suspended scattering particles in motion (SSPiMs) in a patient with exudative reticular pseudodrusen (ERPD) are reported using multimodal imaging modalities. An 82-year-old woman was referred because of persistent macular edema during intravitreal injections of bevacizumab. ERPD associated with types I and II (mixed type) macular neovascularization in both eyes was diagnosed. Bilateral flat irregular pigment epithelial detachments were associated with macular neovascularization in both eyes by optical coherence tomography. An intense oval hypersignal was found at umbo in her right eye, as detected by en face optical coherence tomography angiography. This avascular hypersignal at umbo was SSPiM. No change was noticed in the appearance of SSPiM after intravitreal injection of aflibercept. However, intraretinal hemorrhage developed in Henle’s fiber layer a month after the second intravitreal injection of aflibercept. Then, several SSPiMs were unveiled in a perifoveal location a month after uncomplicated cataract surgery. The SSPiMs that developed after cataract surgery were connected to the capillaries in the deep retinal vascular plexus. Temporary SSPiMs could be seen during injections of anti-vascular endothelial growth factor and after cataract surgery in the same eye of a patient with ERPD. SSPiMs detected by optical coherence tomography angiography were neither artifacts nor hypersignals due to neovascularized vessels. SSPiMs were considered to be a unique phase colloidal phenomenon generating pseudoflow in exudative macular disorders.
© 2023 The Author(s). Published by S. Karger AG, Basel
References
Mimoun G, Soubrane G, Coscas G. Les drusen maculae’s [Macular drusen]. J Fr Ophtalmol. 1990;13(10):511–30.
Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63(6):782–815.
Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 2010;117(2):303–12.e1.
Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, et al. Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(7):1530–40.
Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina. 1995;15(3):183–91.
Querques G, Querques L, Forte R, Massamba N, Coscas F, Souied EH. Choroidal changes associated with reticular pseudodrusen. Invest Ophthalmol Vis Sci. 2012;53(3):1258–63.
de Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical coherence tomography angiography (OCTA). Int J Retina Vitreous. 2015;151:5.
Kashani AH, Green KM, Kwon J, Chu Z, Zhang Q, Wang RK, et al. Suspended scattering particles in motion: a novel feature of OCT angiography in exudative maculopathies. Ophthalmol Retina. 2018;2(7):694–702.
Durlu YK. Response to treatment with anti-vascular endothelial growth factors in bilateral exudative cuticular drusen. Am J Ophthalmol Case Rep. 2021;22:10110.
Tso MO. Pathology of cystoid macular edema. Ophthalmology. 1982;89(8):902–15.
Peng J, Zhong L, Ma L, Jin J, Zheng Y, Jin C. Comparison of vascular parameters between normal cynomolgus macaques and healthy humans by optical coherence tomography angiography. BMC Ophthalmol. 2019;19(1):204.
Curcio CA, Messinger JD, Sloan KR, McGwin G, Medeiros NE, Spaide RF. Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, topography and biogenesis model. Retina. 2013;33(2):265–76.
Author Contacts
Yusuf Kemal Durlu, yusuf@durlu.com
Article / Publication Details
Received: September 24, 2022
Accepted: December 16, 2022
Published online: February 14, 2023
Issue release date: January – December
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 0
eISSN: 1663-2699 (Online)
For additional information: https://www.karger.com/COP
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)